{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:58:43Z","timestamp":1790769523269,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clml.2026.09.001","type":"journal-article","created":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T06:43:41Z","timestamp":1788677021000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Progressive Multifocal Leukoencephalopathy Following Bispecific Antibody Therapy in Multiple Myeloma: A Case Series"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5736-2460","authenticated-orcid":false,"given":"Tyler B.","family":"Sandahl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morie","family":"Gertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6890-969X","authenticated-orcid":false,"given":"Wilson I.","family":"Gonsalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2445-6087","authenticated-orcid":false,"given":"Vy","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dingli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clml.2026.09.001_bib0001","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/ejh.13909","article-title":"Progressive multifocal leukoencephalopathy in multiple myeloma","volume":"110","author":"Hoeynck","year":"2023","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2026.09.001_bib0002","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41582-020-00427-y","article-title":"Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease","volume":"17","author":"Cortese","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.clml.2026.09.001_bib0003","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"NEJM"},{"issue":"suppl 1","key":"10.1016\/j.clml.2026.09.001_bib0004","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1182\/blood-2025-701","article-title":"Safety and efficacy of Talquetamab + teclistamab in patients with relapsed\/refractory multiple myeloma from phase 1B of redirect-1: results with an extended median follow-up of 3 years","volume":"146","author":"Mateos","year":"2025","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.clml.2026.09.001_bib0005","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for treatment of relapsed\/refractory multiple myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.09.001_bib0006","series-title":"Prescribing Information","year":"2025"},{"key":"10.1016\/j.clml.2026.09.001_bib0007","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 magnetismm-3 trial results","volume":"28","author":"Lesokhin","year":"2023","journal-title":"Nature Med"},{"issue":"8","key":"10.1016\/j.clml.2026.09.001_bib0008","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7048","article-title":"Effectiveness and infectious complications of BCMA T-cell engagers in treating multiple myeloma: real-world evidence from Sweden","volume":"13","author":"Utterval","year":"2024","journal-title":"Cancer Med"},{"issue":"6","key":"10.1016\/j.clml.2026.09.001_bib0009","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.cmi.2024.02.023","article-title":"Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study","volume":"30","author":"Jourdes","year":"2024","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"10.1016\/j.clml.2026.09.001_bib0010","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/ana.410180412","article-title":"Progressive multifocal leukoencephalopathy: investigation of three cases using in situ hybridization with JC virus biotinylated DNA probe","volume":"18","author":"Aksamit","year":"1985","journal-title":"Ann Neurol"},{"issue":"15","key":"10.1016\/j.clml.2026.09.001_bib0011","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","article-title":"PML diagnostic criteria: consensus statement from the AAN neuroinfectious disease section","volume":"80","author":"Berger","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.clml.2026.09.001_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2026.1692522","article-title":"Progressive multifocal leukoencephalopathy \u2013 a diagnostic guide for the clinical neurologist","volume":"17","author":"Jia","year":"2026","journal-title":"Front Neurol"},{"key":"10.1016\/j.clml.2026.09.001_bib0013","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.clml.2026.09.001_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-020-04294-x","article-title":"Progressive multifocal leukoencephalopathy in multiple myeloma. A literature review and lessons to learn","volume":"100","author":"Koutsavlis","year":"2020","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1016\/j.clml.2026.09.001_bib0015","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.3390\/curroncol31050202","article-title":"Progressive multifocal leukoencephalopathy unmasked by teclistamab in a refractory multiple myeloma patients","volume":"31","author":"Arvanitis","year":"2024","journal-title":"Curr Oncol"},{"key":"10.1016\/j.clml.2026.09.001_bib0016","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2025.300331","article-title":"Late-onset progressive multifocal leukoencephalopathy after teclistamab in multiple myeloma: extending the timeline of infectious risk","author":"Chizzoniti","year":"2026","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.clml.2026.09.001_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2026.01.017","article-title":"Progressive multifocal leukoencephalopathy (PML) in 2 patients treated with elranatamab","volume":"26","author":"Tomkins","year":"2026","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.clml.2026.09.001_bib0018","first-page":"431","article-title":"Progressive multifocal leukoencephalopathy and BK virus-nephropathy with bispecific antibody therapy in multiple myeloma","volume":"111","author":"Siegel","year":"2026","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.09.001_bib0019","article-title":"Progressive multifocal leukoencephalopathy in a multiple myeloma patient treated with teclistamab and talquetamab","volume":"4162698","author":"Udovica","year":"2025","journal-title":"EHA Library"},{"key":"10.1016\/j.clml.2026.09.001_bib0020","article-title":"Progressive multifocal leukoencephalopathy associated with elranatamab therapy in relapsed\/refractory multiple myeloma","author":"Cetiner","year":"2026","journal-title":"J Oncol Pharm Practice"},{"key":"10.1016\/j.clml.2026.09.001_bib0021","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1815039","article-title":"Pembrolizumab treatment for progressive multifocal leukoencephalopathy","volume":"380","author":"Cortese","year":"2019","journal-title":"NEJM"},{"issue":"11","key":"10.1016\/j.clml.2026.09.001_bib0022","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1001\/jamaneurol.2024.3324","article-title":"Directly isolated allogeneic virus-specific T cells in progressive multifocal leukoencephalopathy","volume":"81","author":"Mohn","year":"2024","journal-title":"JAMA Neurol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026032878?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026032878?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:19:14Z","timestamp":1790767154000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026032878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":22,"alternative-id":["S2152265026032878"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.09.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progressive Multifocal Leukoencephalopathy Following Bispecific Antibody Therapy in Multiple Myeloma: A Case Series","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}